earnings digest health forest laboratories inc forest laboratories inc reported a increase in net income in its fiscal third quarter helped largely by strong sales of its antidepressant lexapro its leading branded product and its alzheimers treatment namenda sales of lexapro rose to &# million from &# million last year while sales of namenda rose to &# million from &# million new york based forest laboratories said that as a result of stronger than expected sales it was raising its earnings outlook for its fiscal year ending in march to a range of &# to &# a share from a prior forecast of &# to &# a share the outlook excludes a one time charge of about &# million or about &# a share from the acquisition of cerexa inc this charge will be recorded in the fourth quarter and is subject to final purchase price valuation and allocation analysts surveyed by thomson financial had been expecting full year profit of &# a share on average 
